- Home
- MOLN vs MYO Comparison
MOLN vs MYO Comparison
Compare MOLN & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- MYO
- Stock Information
- Founded
- MOLN 2004
- MYO 2004
- Country
- MOLN Switzerland
- MYO United States
- Employees
- MOLN N/A
- MYO N/A
- Industry
- MOLN
- MYO Industrial Specialties
- Sector
- MOLN
- MYO Health Care
- Exchange
- MOLN Nasdaq
- MYO Nasdaq
- Market Cap
- MOLN 138.6M
- MYO 153.0M
- IPO Year
- MOLN 2021
- MYO 2017
- Fundamental
- Price
- MOLN $3.59
- MYO $2.12
- Analyst Decision
- MOLN
- MYO Strong Buy
- Analyst Count
- MOLN 0
- MYO 4
- Target Price
- MOLN N/A
- MYO $9.13
- AVG Volume (30 Days)
- MOLN 1.9K
- MYO 777.8K
- Earning Date
- MOLN 08-25-2025
- MYO 08-05-2025
- Dividend Yield
- MOLN N/A
- MYO N/A
- EPS Growth
- MOLN N/A
- MYO N/A
- EPS
- MOLN N/A
- MYO N/A
- Revenue
- MOLN $2,525,030.00
- MYO $38,628,624.00
- Revenue This Year
- MOLN N/A
- MYO $55.29
- Revenue Next Year
- MOLN $866.67
- MYO $27.18
- P/E Ratio
- MOLN N/A
- MYO N/A
- Revenue Growth
- MOLN N/A
- MYO 97.60
- 52 Week Low
- MOLN $3.36
- MYO $2.02
- 52 Week High
- MOLN $12.22
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- MOLN 43.66
- MYO 38.86
- Support Level
- MOLN $3.71
- MYO $2.02
- Resistance Level
- MOLN $3.89
- MYO $2.89
- Average True Range (ATR)
- MOLN 0.10
- MYO 0.15
- MACD
- MOLN -0.01
- MYO 0.04
- Stochastic Oscillator
- MOLN 20.00
- MYO 43.94
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).